Starting the End-of-Life Conversation

Slideshow

End-of-life care is challenging for even the most seasoned oncologist. Here are five suggestions that can help you better navigate this difficult but critical part of your work.

slideshow image

End-of-life care is challenging for even the most seasoned oncologist. Here are five suggestions that can help you better navigate this difficult but critical part of your work.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Staged Colectomy May Be Preferable to Upfront Colectomy in Appendix Cancer
Staged Colectomy May Be Preferable to Upfront Colectomy in Appendix Cancer
Comprehensive prehabilitation may help prepare patients for bladder-preserving surgery, helping to optimize quality of life outcomes.
Reviewing QOL Strategies/Considerations Following Bladder Cancer Surgery
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
CRC Yields Most Prevalent Data at Recent GI Meeting
No Subgroups Benefit From HIPEC/CRS in Colorectal Peritoneal Metastasis
No Subgroups Benefit From HIPEC/CRS in Colorectal Peritoneal Metastasis
4 experts in this video
Imaging Quality in Prostate Cancer: Impact on Treatment Decision-Making
Exploring Next-Line Options: Therapies Beyond Trastuzumab Deruxtecan in HER2+ MSS Gastric Cancer
Exploring Next-Line Options: Therapies Beyond Trastuzumab Deruxtecan in HER2+ MSS Gastric Cancer
4 experts in this video
Selecting the Optimal PSMA PET Imaging Agent: Clinical Considerations and Data-Driven Decisions
Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
Outlining Risk Factor Identification and Mitigation in Bladder Cancer
MSS Status and Pembrolizumab: Assessing Benefits and Considering Combinations Beyond Progression in Upper GI Cancer
MSS Status and Pembrolizumab: Assessing Benefits and Considering Combinations Beyond Progression in Upper GI Cancer
HIPEC/CRS Confers No Benefit, Adds Risk in Colorectal Peritoneal Metastases
HIPEC/CRS Confers No Benefit, Adds Risk in Colorectal Peritoneal Metastases
Related Content
Postoperative complications and mortality after standard or postponed surgery for esophageal cancer after active surveillance were similar in both groups.

Active Surveillance Shows Noninferior OS vs Surgery in Esophageal Cancer

Roman Fabbricatore
April 5th 2025
Article

Postoperative complications and mortality after standard or postponed surgery for esophageal cancer after active surveillance were similar in both groups.

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
April 1st 2025
Podcast

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

The pre-specified number of events required to undergo analyses of the secondary end points, including PFS, OS, and DOR, have not been met.

Tovecimig Yields Significant Responses in Advanced Biliary Tract Cancer

Roman Fabbricatore
April 4th 2025
Article

The pre-specified number of events required to undergo analyses of the secondary end points, including PFS, OS, and DOR, have not been met.

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Improving NSCLC Surgery Recovery After Climate Disaster Exposure

Leticia Nogueira, PhD, MPH
March 31st 2025
Podcast

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Telehealth Groups May Improve the Social Lives of Young Cancer Populations

Telehealth Groups May Improve the Social Lives of Young Cancer Populations

Tim Cortese
April 3rd 2025
Article

Most patients with cancer who took part in a telehealth group expressed that they liked the members of their group and felt less social isolation.

A futility analysis showed that ociperlimab was unlikely to reach the primary end point of overall survival as part of the phase 3 AdvanTIG-302 trial.

Developers Terminate Clinical Program for Ociperlimab in Lung Cancer

Russ Conroy
April 3rd 2025
Article

A futility analysis showed that ociperlimab was unlikely to reach the primary end point of overall survival as part of the phase 3 AdvanTIG-302 trial.